Drugs For Treatment Of Constipation Market - Industry Analysis, Market - Forecast(2025 - 2031)

Drugs for Treatment of Constipation Industry Market Overview

The Drugs for Treatment of Constipation Industry Market size is estimated to reach $15.72 billion by 2030, growing at a CAGR of 6% during the forecast period 2024-2030. Constipation Treatment normally starts with diet and lifestyle alterations. Laxatives are materials that influence the intestines in a way that causes bowel activity. Polyethylene glycol with or without electrolytes is more effective than a placebo for the treatment of functional constipation. Methylcellulose fiber is utilized to treat constipation and to assist in keeping up normal bowel movements. Currently, numerous opioid receptor antagonists have been presented in the treatment of Opioid-induced constipation (OIC). Lactulose is a kind of sugar utilized to treat constipation. As per investigations, linaclotide seems to be a well-tolerated and efficient agent for patients with chronic constipation. The constant R&D to establish new medications to treat constipation is set to drive the Drugs for Treatment of Constipation Industry Market. The Drugs for Treatment of Constipation Industry Market is witnessing a paradigm shift with the emergence of personalized therapies tailored to individual patient needs. Recent developments focus on leveraging genetic and microbiome data to understand the root causes of constipation. This approach allows healthcare providers to develop targeted treatments, addressing specific underlying factors contributing to constipation. Personalized therapies enhance treatment efficacy, reduce side effects, and improve patient outcomes. With advancements in precision medicine, pharmaceutical companies are investing in research and development to create innovative drugs that consider the unique biological profiles of patients, ushering in a new era of customized constipation treatment. The integration of digital health solutions is transforming the landscape of constipation treatment. Innovations like mobile applications, wearable devices, and telemedicine platforms are playing a pivotal role in monitoring and managing constipation. These technologies enable real-time tracking of patient symptoms, medication adherence, and lifestyle factors affecting bowel health. Moreover, they facilitate remote patient-doctor communication, empowering individuals to receive timely advice and adjustments to their treatment plans. The incorporation of artificial intelligence in data analysis further enhances diagnostic accuracy and predictive modeling for effective constipation management. The increasing adoption of digital health solutions not only improves patient engagement but also streamlines healthcare delivery, contributing to the overall growth of the Drugs for Treatment of Constipation Industry Market. The surging application of methylcellulose fiber for constipation treatment is set to propel the Constipation Treatment Industry during the forecast period 2024-2030. This represents the Constipation Treatment Industry Outlook.

Market Snapshot :

Drugs for Treatment of Constipation Industry Market Report Coverage

The “Drugs for Treatment of Constipation Industry Market Report - Forecast (2024-2030)” by Industry ARC, covers an in-depth analysis of the following segments in the Drugs for Treatment of Constipation Industry Market.

By Therapeutic: Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists, 5-HT4 Receptor Agonists and Others.

By Disease Type: Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome With Constipation (IBS-C) and Opioid-Induced Constipation (OIC).

By Prescription Type: Prescribed Drugs, Over-the-Counter Drugs

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

By Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

• Geographically, North America (Drugs for Treatment of Constipation Industry Market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2024-2030. The growth would be driven by the increasing predominance of incessant constipation requiring the application of methylcellulose fiber in the North American region.
• Drugs for Treatment of Constipation Industry Market growth is being driven by the expanding count of elderly patients. However, the rising reliance on over-the-counter (OTC) medications is one of the major factors hampering the growth of the Drugs for Treatment of Constipation Industry Market.
• Drugs for Treatment of Constipation Industry Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Drugs for Treatment of Constipation Industry Market report.

 
For More Details on This Report - Request for Sample

Drugs for Treatment of Constipation Industry Market Segment Analysis - by Therapeutic

The Drugs for Treatment of Constipation Industry Market based on therapeutic can be further segmented into Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists, 5-HT4 Receptor Agonists and Others. The Peripherally Acting Mu-Opioid Receptor Antagonists Segment held the largest Drugs for Treatment of Constipation Industry Market share in 2021. This growth is owing to the accessibility of different kinds of products launched by key players suited for different symptoms in OIC. The surging research activities and accessibility of Mu-Opioid Receptor Antagonists are further propelling the growth of the Peripherally Acting Mu-Opioid Receptor Antagonists segment. Furthermore, the Chloride Channel Activators segment is estimated to grow with the fastest CAGR of 7.1% during the forecast period 2024-2030. That is because of the soaring application of lubiprostone, approved by the U.S. Food and Drug Administration (FDA), for the treatment of chronic constipation.

Drugs for Treatment of Constipation Industry Market Segment Analysis - by Distribution Channel

The Drugs for Treatment of Constipation Industry Market based on distribution channels can be further segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The Hospital Pharmacies segment held the largest Drugs for Treatment of Constipation Industry Market share in 2023. This growth is caused by the extensive application of hospital pharmacies for the production, stockpiling and delivery of medications to inpatients. Opioid Receptor Antagonists, lactulose and linaclotide may be available in hospital pharmacies. The wider choice of pharmaceuticals in hospital pharmacies is further propelling the growth of this segment. Furthermore, the Online Pharmacies segment is estimated to grow with the fastest CAGR of 6.8% during the forecast period 2024-2030. This is due to the surging application of online pharmacies for the effortless purchase of medications for constipation treatment like polyethylene glycol, lactulose and linaclotide at just a click of the mouse at fingertips.

Drugs for Treatment of Constipation Industry Market Segment Analysis - by Geography

North America held the largest Drugs for Treatment of Constipation Industry Market share with 40% of the overall market in 2030. The growth of this region is owing to the increasing predominance of chronic constipation that requires the application of lactulose and linaclotide in the North American region. The burgeoning financing in healthcare is further propelling the growth of the Constipation Treatment Industry, thereby contributing to the Constipation Treatment Industry Outlook in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2024-2030. This growth is fuelled by factors like the rising predominance of chronic constipation in the Asia-Pacific region. The surging accessibility of Prucalopride for chronic constipation is further fuelling the progress of the Drugs for Treatment of Constipation Industry Market in the Asia-Pacific region.

Drugs for Treatment of Constipation Industry Market Drivers

Surging Applications of Methylcellulose Fiber:

Methylcellulose (Citrucel) comes under the category of bulk-forming laxatives. It boosts the bulk of stools leading to enhanced intestinal motility and regulating bowel activities. It is utilized as an adjunct to diet and additional therapies in the treatment of constipation and to restore & maintain bowel regularity. For children aged 6 to 11 years, one caplet of Citrucel tablet, as needed up to six times per day, may be recommended for the treatment of constipation. The maximum dose per day is 6 caplets. The surging applications of Methylcellulose Fiber are therefore fuelling the growth of the Drugs for Treatment of Constipation Industry Market during the forecast period 2024-2030.

Proliferating Applications of Opioid Receptor Antagonists:

Opioid antagonists not only have entrenched indications in the reversal of life-alarming opioid toxicity but also hold significant promise for additional applications in palliative care practice, specifically in handling of opioid-induced constipation (OIC). Currently, numerous opioid receptor antagonists have been presented in the treatment of OIC. Methylnaltrexone (MNTX) is designated for patients with OIC who are not agreeable to therapy with oral laxatives. In clinical trials, the efficiency of MNTX assessed as its ability to induce a spontaneous bowel movement is 50%-60% of treated patients. The proliferating applications of Opioid Receptor Antagonists are therefore driving the growth of the Constipation Treatment Industry, thereby contributing to the Constipation Treatment Industry Outlook during the forecast period 2024-2030.

Drugs for Treatment of Constipation Industry Market Challenge

Extensive Investigative Approach for Constipation Treatment:

Constipation excessively influences older mature grown-ups, with a predominance of 50% in community-dwelling elderly and 74% in nursing-home residents. Hirschsprung's disease is the most recognized organic kind of constipation. However, there are additional neurogenic and myogenic abnormalities of the colonic (and/or ileal) tract that imitate Hirschsprung's disease and symbolize development abnormalities of the enteric nervous plexus. Additional organic kinds of constipation are caused by systemic ailments, endocrine and metabolic disorders and central nervous system disorders. Organic constipation normally needs an extensive investigative approach, inclusive of pathologic examination of the enteric nervous plexus on full-thickness biopsies. These issues are thus hampering the growth of the Drugs for Treatment of Constipation Industry Market.

Drugs for Treatment of Constipation Industry Outlook

Novel product launches, mergers, acquisitions, partnerships, collaborations, considerable financing by key players and R&D activities are key strategies adopted by players in the Drugs for Treatment of Constipation Industry Market. The top 10 companies in the Constipation Treatment industry are:

1. Takeda Pharmaceutical Company Ltd.
2. Ironwood Pharmaceuticals, Inc.
3. Salix Pharmaceuticals, Inc.
4. Abbott Laboratories
5. AstraZeneca Plc
6. Cosmo Pharmaceuticals NV
7. Sanofi S.A.
8. Bayer AG
9. AbbVie Inc.
10. Pfizer Inc.

Recent Developments

• In January 2022, Takeda stressed a strategy for conveying sustainable development over the next ten years at the 40th Annual J.P. Morgan Healthcare Conference. Takeda’s powerful pipeline includes nearly 40 diverse, clinical-stage assets. They would offer the promise of a considerable count of regulatory approvals.
• In April 2022, Ardelyx, Inc. announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is the first FDA-approved product for Ardelyx.
• In May 2023, Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases.

For more Lifesciences and Healthcare Market reports, please click here